Key clinical point : Time to progression of disease (POD), defined as the time between first-line rituximabâbased therapy initiation and disease progression before second-line Bruton tyrosine kinase inhibitor (BTKi) therapy initiation , is associated with survival outcomes in patients with relapsed or refractory mantle cell lymphoma (MCL) receiving second-line BTKi therapy.
Major finding: After initiating second-line BTKi therapy, patients with POD within vs after 24 months of first-line therapy had significantly shorter median progressionâfree survival (0.45 vs 2.3 years; P < .001) and overall survival (0.9 vs 5.5 years; P < .001).
Study details: This multicenter retrospective observational study included 360 adult patients with relapsed or refractory MCL who initiated second-line BTKi therapy after first-line rituximab-based therapy.
Disclosures: No information on the source of funding was provided. Some authors declared serving as consultants or advisors and receiving research funding, speaker fees, or honoraria from various sources.
Source: Villa D et al. Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma. Blood Adv. 2023 (Jun 12). Doi: 10.1182/bloodadvances.2023009804